Celularity Presents Preclinical Data on CYNK-101, its Allogeneic Genetically-Modified Natural Killer Cell Therapy Candidate, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting

November 10, 2022

https://www.globenewswire.com/news-release/2022/11/10/2553388/0/en/Celularity-Presents-Preclinical-Data-on-CYNK-101-its-Allogeneic-Genetically-Modified-Natural-Killer-Cell-Therapy-Candidate-at-the-Society-for-Immunotherapy-of-Cancer-s-37th-Annual-.html

FLORHAM PARK, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq:CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, today announced that it will present preclinical data on the development of its novel placental-derived allogeneic genetically modified natural killer (NK) cell therapy program CYNK-101 in combination with avelumab. Celularity will report its findings in a poster presentation at the 37th Annual Meeting of The Society for Immunotherapy of Cancer (SITC) taking place in Boston, Massachusetts and virtually November 8-12, 2022.

Read more at globenewswire.com

Related news for (CELU)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.